Cerebral Perfusion Studies with Technetium-99m HMPAO

Part of the Developments in Nuclear Medicine book series (DNUM, volume 25)


Technetium-99m Hexamethylpropyleneamine oxine [HMPAO] diffuses rapidly across the blood brain barrier. Following intravenous injection the bulk of the intracerebral accumulation takes place during the first and second transits through the cerebral vessels. Diffusion of the complex across the blood brain barrier into the brain cells is related to the neutral charge on the molecule, its lipophilicity [1] but also to its isomeric form [2]. Maximum uptake of the d-l isomer in cerebro is reached at ±2 minutes post injection at which time ± 2% of the injected dose is retained. Intracellular retention is not related to receptor sites but would appear to be related to changes in lipophilicity. The rate of release of labelled complex is extremely slow, less than 1% per hour [3].


Chronic Fatigue Syndrome Cerebral Perfusion Regional Cerebral Blood Flow Frontotemporal Dementia Normal Pressure Hydrocephalus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Volkert WA, et al. Technetium-99m propyleneamine oxine for brain imaging. J Nucl Med 1983;24:128 [abstract]Google Scholar
  2. 1a.
    Volkert WA, et al. The behaviour of neutral amine oxine chelates labelled with technetium at tracer level. Int J Nucl Med Biol 1984;11:243–46.CrossRefPubMedGoogle Scholar
  3. 2.
    Nowotnik DP, et al. Development of a Tc-99m labelled radiopharmaceutical for cerebral blood flow imaging. Nucl Med Comm 1985;6:499–506.CrossRefGoogle Scholar
  4. 3.
    Canning LR, et al. 1988. US Patent 4789736 and others.Google Scholar
  5. 4.
    Costa DC, Ell PJ, editors. Brain blood flow in neurology and psychiatry. London: Churchill Livingstone 1991:183.Google Scholar
  6. 5.
    Stefan H, et al. Initial experience with 99m-Tc-Hexamethylpropyleneamine oxine [HPMAO] in patients with focal epilepsy. Epilepsy Res 1987;1:134–38.CrossRefPubMedGoogle Scholar
  7. 6.
    Biersack JK, et al. Tc-99m labelled HMPAO photon emission scans in epilepsy. Lancet 1985; 1436–37.Google Scholar
  8. 7.
    Ring HA, et al. The use of cerebral activation procedures with single photon emission tomography. Eur J Nucl Med 1991;18:133–41.CrossRefPubMedGoogle Scholar
  9. 8.
    Larsson A, et al. Regional cerebral blood flow in normal pressure hydrocephalus. diagnostic and prognostic aspects. Eur J Nucl Med 1994;21:118–23.CrossRefPubMedGoogle Scholar
  10. 9.
    Babich JW, et al. Initial experience with Tc-99m-HM-PAO in the study of brain tumours. Eur J Nucl Med 1988;14:39–44.CrossRefPubMedGoogle Scholar
  11. 10.
    Rodrigues M, et al. 99m-Tc-HMPAO brain SPECT in the evaluation of prognosis after surgical resection of astrocytoma. Comparison with other noninvasive imaging techniques [CT,MRI and Tl-201 SPECT]. Nucl Med Comm 1993;14:1050–60.CrossRefGoogle Scholar
  12. 11.
    Gemmel HG, et al. Differential diagnosis in dementia using the cerebral blood flowagent Tc-99m HMPAO. A SPECT study. J Comput Assist Tomogr 1987; 11:398–402.CrossRefGoogle Scholar
  13. 12.
    Perani D, et al. Technetium-99m HMPAO SPECT study of regional cerebral perfusion in Alzheimers disease. J Nucl Med 1988;29:1507–14.PubMedGoogle Scholar
  14. 13.
    Gemmell HG. A comparison of Tc-99m HM-PAO and I-123 IMP cerebral SPECT images in Alzheimers disease and multi-infarct dementia. Eur J Nucl Med 1988;14:463–66.CrossRefPubMedGoogle Scholar
  15. 14.
    Grant DJ, et al. HMPAO SPECT a diagnostic test for Alzheimers disease in a memory clinic? Nucl Med Comm 1994;15:252 [abstract].CrossRefGoogle Scholar
  16. 15.
    Johnson KA, et al. Quantitative brain SPECT in Alzheimers disease and normal aging. J Nucl Med 1993;34:2044–48.PubMedGoogle Scholar
  17. 16.
    Hellman RS, et al. A multi-institutional study of interobserver agreement in the evaluation of dementia with rCBF/SPET Technetium-99m exametazine [HMPAO]. Eur J Nucl Med 1994;21:306–13.CrossRefPubMedGoogle Scholar
  18. 17.
    Smith FW, et al. Technetium-99m HMPAO imaging in patients with basal ganglia disease. Br J Radiol 1988;61:914–20.CrossRefPubMedGoogle Scholar
  19. 18.
    Costa DC, et al. Brain stem SPET studies in normals, ME/CFS and depression. Nucl Med Commun 1994; 15:252 [Abstract].CrossRefGoogle Scholar
  20. 19.
    Lassen NA. Imaging brain infarcts by single photon emission tomography with new tracers. Eur J Nucl Med 1994;21:189–90.CrossRefPubMedGoogle Scholar
  21. 20.
    Moretti JL, et al. Luxury perfusion with Tc-99m HMPAO and Iodine-123 IMP SPECT imaging during the subacute phase of stroke. Eur J Nucl Med 1990; 16:17– 22.CrossRefPubMedGoogle Scholar
  22. 21.
    Sperling B, Lassen NA. Hyperfixation of HMPAO in subacute ischemic stroke leading to spuriously high estimates of cerebral blood flow by SPET. Stroke 1993;24:193–94.CrossRefPubMedGoogle Scholar
  23. 22.
    Yeh SH, et al. Brain SPECT imaging with technetium-99m hexamethylpropyleneamine oxime in the early detection of cerebral infarction: comparison with computed tomography. Nucl Med Commun 1986;7:873–78.CrossRefPubMedGoogle Scholar
  24. 23.
    Oku N, et al. Carbon dioxide reactivity by consecutive Technetium-99m HMPAO SPECT in patients with a chronically obstructed major cerebral artery. J Nucl Med 1994;35:32–40.PubMedGoogle Scholar
  25. 24.
    Talbot PR, et al. The psychological and SPET correlates of frontotemporal cerebral atrophy. Nucl Med Commun 1994; 15:252.[Abstract].Google Scholar
  26. 25.
    Talbot PR, et al. Frontotemporal dementia and motor neurone disease SPET and psychological correlates. Nucl Med Comm 1994(2); 15.252 [Abstract].Google Scholar
  27. 26.
    Hayashida K, et al. Detection of postural cerebral hypoperfusion with Technetium-99m-HMPAO brain SPECT in patients with cerebrovascular disease. J Nucl Med 1993;34:1931–35.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1995

Authors and Affiliations

There are no affiliations available

Personalised recommendations